2000
DOI: 10.1634/theoncologist.5-4-293
|View full text |Cite
|
Sign up to set email alerts
|

Prophylactic Cranial Irradiation in Small-Cell Lung Cancer

Abstract: Prophylactic cranial irradiation is now known to improve survival to a significant degree in small-cell lung cancer (SCLC) patients; this is in addition to its established role in preventing the disabling symptoms of brain metastases. New information indicates that it confers a survival benefit for limited or extensive stage SCLC patients gaining a complete response in the chest. A review of causes of cerebral dysfunction as a complication indicates that such problems can be due to suboptimal radiation fractio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
25
0

Year Published

2002
2002
2019
2019

Publication Types

Select...
3
3
2

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(26 citation statements)
references
References 29 publications
1
25
0
Order By: Relevance
“…[33][34][35][36] PCI is part of the standard treatment protocol for SCLC patients. 17 However, over the past 25 years, the diagnostic tools used to stage and evaluate SCLC patients have evolved.…”
Section: } }mentioning
confidence: 99%
“…[33][34][35][36] PCI is part of the standard treatment protocol for SCLC patients. 17 However, over the past 25 years, the diagnostic tools used to stage and evaluate SCLC patients have evolved.…”
Section: } }mentioning
confidence: 99%
“…The results of several randomized trials and meta-analyses have shown that PCI reduces the incidence of brain metastases in patients with LS SCLC [1,13,18,32,36]. Application of PCI lowers the frequency of brain metastases (from 54% without PCI to 30% with PCI) and increases the survival rate (by 5.4% for 3-year overall survival) [3,9,21].…”
Section: Introductionmentioning
confidence: 99%
“…The results of several randomized trials and meta-analyses have shown that PCI reduces the incidence of brain metastases in patients with LS SCLC [1,13,18,32,36]. Application of PCI lowers the frequency of brain metastases (from 54% without PCI to 30% with PCI) and increases the survival rate (by 5.4% for 3-year overall survival) [3,9,21].The investigations of improvement efficiency of PCI refer to the total dose of PCI and timing of PCI in relation to chemoradiotherapy [19,27,36].The aim of this study is to evaluate the effectiveness of PCI timing in patients with LS SCLC. …”
mentioning
confidence: 99%
“…The incidence of BM is directly proportional with the survival time, indicating a potential for further increase with implementation of more effective treatment protocols (Komaki, 1981;van Oosterhout, 1996). Compared to patients with LS-SCLC, the risk for BM occurrence is higher for patients with ES-SCLC reaching 69% at 2-years of diagnosis (van Oosterhout, 1996;Yang GY & Matthews, 2000). Impact of BM on socioeconomic issues and quality of life is significantly worse than the impact of failure at other metastatic sites.…”
Section: Prophylactic Cranial Irradiationmentioning
confidence: 99%